Scott Wofford

Appearances

FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Date
May 21, 2024
Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
Presenter
Evan Dellon
University of North Carolina School of Medicine
Speakers
Gary Falk
Unversity of Pennsylvania
Jeffrey Rumbyrt
Scott Wofford
David Bernstein
Paul Feuerstadt
Paul Lamb
John Leung
Gina Eagle
James Nezamis
Vered Katz Ben-Yair
Ikuo Hirano
FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Date
May 21, 2024
The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…
Presenter
Evan Dellon
University of North Carolina School of Medicine
Speakers
Gary Falk
Unversity of Pennsylvania
Jeffrey Rumbyrt
Scott Wofford
David Bernstein
Paul Feuerstadt
Paul Lamb
John Leung
Gina Eagle
James Nezamis
Vered Katz Ben-Yair
Ikuo Hirano